Result for
Topic: Vaccines and Immunity
February 3, 2021
Neutralization of SARS-CoV-2 VOC 501Y.V2 by Human Antisera Elicited by Both Inactivated BBIBP-CorV and Recombinant Dimeric RBD ZF2001 Vaccines
[Pre-print, not peer-reviewed] Sera from 12 participants who received either the inactivated virus vaccine BBIP-CorV or the ZF2001 RBD protein subunit vaccine (both manufactured in China) showed neutralizing activity against the 501Y.V2 SARS-CoV-2 variant (first identified in South Africa). Neutralization was measured by microcytopathogenic effect assay and there were slightly reduced geometric mean antibody titers…
February 2, 2021
Effect of RBD (Y453F) Mutation in Spike Glycoprotein of SARS-CoV-2 on Neutralizing IgG Affinity
[Pre-print, not peer reviewed] A mutation found in farm minks infected with SARS-CoV-2 (Y435F) was predicted to lead to reduced binding to the human ACE-2 receptor, and was experimentally shown to alter the affinity of convalescent polyclonal serum to the receptor binding domain (RBD). Using a modified ELISA assay, strong affinity to recombinant non-mutated RBD…
Articles Safety and Efficacy of an RAd26 and RAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine: An Interim Analysis of a Randomised Controlled Phase 3 Trial in Russia
Interim analysis of the randomized, double-blind, placebo-controlled phase 3 trial for the recombinant adenovirus (rAd)-based vaccine Gam-COVID-Vac (Sputnik V) (n=19,866) showed an efficacy of 91.6% (CI: 85.6%-95.2%) by 21 days after the first dose of vaccine (the day of dose 2). 16 of 14,964 (0.1%) people in the vaccine group developed COVID-19 compared to 62…
February 1, 2021
Impact of Age Gender Ethnicity and Prior Disease Status on Immunogenicity Following Administration of a Single Dose of the BNT162b2 MRNA Covid-19 Vaccine Real-World Evidence from Israeli Healthcare Workers December-January 2020
[Pre-print, not peer-reviewed] Among 514 healthcare workers in Israel who received a SARS-CoV-2 vaccine (majority Pfizer), 92% had detectable IgG antibodies 21 days post-vaccination. There was no statistically significant difference in antibody titers between males and females or by ethnicity, but titers decreased with increasing age. Individuals with prior COVID-19 who received the vaccine had…
Mapping a Pandemic SARS-CoV-2 Seropositivity in the United States
[Pre-print, not peer-reviewed] Between May and July 2020, there were an estimated 4.8 undiagnosed cases of COVID-19 for every case diagnosed in the United States, and an estimated 16.8 million undiagnosed cases by mid-July, based on findings from a serostudy conducted among adults (n = 11,3182) who had not been diagnosed with COVID-19. Undiagnosed seropositivity…
Early COVID-19 First-Dose Vaccination Coverage Among Residents and Staff Members of Skilled Nursing Facilities Participating in the Pharmacy Partnership for Long-Term Care Program — United States, December 2020–January 2021. MMWR
As of January 17, 2021, a median of 77.8% of residents (IQR: 61.3-93.1%) and 37.5% of staff members (IQR: 23.2-56.8%) across 11,460 skilled nursing facilities received ≥1 vaccine dose through the CDC Pharmacy Partnership for Long-Term Care Program, a public-private partnership between the CDC and CVS, Walgreens, and Managed Healthcare Associates. A total of 713,909…
Robust Spike Antibody Responses and Increased Reactogenicity in Seropositive Individuals after a Single Dose of SARS-CoV-2 MRNA Vaccine
[Pre-print, not peer-reviewed] One dose of mRNA vaccine elicited a rapid and strong immune response among individuals already seropositive for SARS-CoV-2, with antibody titers 10-20 times higher than those of naïve vaccinees at the same timepoint. Seropositive individuals also had antibody titers that exceeded by >10-fold the median titers among individuals without previous infection who…
Post-Vaccination COVID-19 among Healthcare Workers, Israel
Among 4,081 vaccinated healthcare workers in Israel, 22 (0.54%) developed laboratory-confirmed COVID-19 between 1–10 days (median 3.5) post-immunization. Among these 22 individuals, 13 were tested because they experienced symptoms including fever, chills, cough, headache, and sore throat. 11 people had suspected community-related exposure, 4 of whom were exposed before their vaccination date. Among symptomatic individuals,…
Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios
IgG antibodies to SARS-CoV-2 from pregnant women with symptomatic or asymptomatic SARS-CoV-2 infection were transferred across the placenta, and cord antibody concentrations were positively correlated with maternal IgG concentrations (r=0.9). IgG antibodies were detected in cord blood from 72 of 83 newborns (87%), while IgM antibodies were not detected in any cord blood samples. Eleven…
Demographic Characteristics of Persons Vaccinated During the First Month of the COVID-19 Vaccination Program — United States, December 14, 2020–January 14, 2021
During the first month of the US COVID-19 vaccination program (December 14, 2020-January 14, 2021) nearly 13 million people received at least one dose of the vaccine. Race/ethnicity was unknown or not reported for 6,222,052 (48.1%) persons initiating vaccination. Among individuals for whom demographic data were available, 63% were women, and 60% were non-Hispanic white,…
Previous page Next page